Company Description: Cytovation is a clinical-stage immuno-oncology biotech focused on the development of CyPep-1, a first-in-class synthetic peptide that has been designed to selectively target cancer cells with a dual mode of action: (1) Selective targeting of the cancer cell plasma membrane releases neoantigens that drive a tumor-specific immune response, (2) inhibition of the Wnt/β-catenin pathway promotes immune activation and reverses immune exclusion. Building on a successful Ph 1 study demonstrating a favorable safety profile and clinical activity in several indications, Cytovation is advancing into Ph 2. The first trial with registration intent will be in metastatic adrenocortical carcinoma (ACC), a rare and highly aggressive tumor type with no approved treatment options after first line. This program will be followed by larger indications with aberrant b-catenin expression, including colorectal cancer and hepatocellular carcinoma.